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Abstract: Tumor lysis syndrome (TLS), a result of rapid cell lysis following tumor therapy, 
is a well recognized complication during the treatment of rapidly growing tumors. TLS rarely 
occurs in solid tumors. We present a case report of TLS in a patient with primary retroperitoneal 
soft tissue sarcoma. TLS occurred in the patient after four days’ combinational chemotherapy 
with cisplatin, adriamycin, and dacarbazine. These drugs were selected on the basis of an 
ex vivo ATP-based tumor sensitivity assay. TLS was properly controlled in the patient with 
concomitant remission of the sarcoma. Therefore, precautions should be taken to avoid this 
potentially fatal complication during treatment of solid tumors, especially with tumors highly 
sensitive to drugs.
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Introduction
Treatment of retroperitoneal soft tissue sarcomas is difﬁ  cult. Adequate tumor-free 
margins are not easily obtained and locoregional recurrence is common following 
surgery for retroperitoneal soft tissue sarcomas. To improve locoregional control, 
various experts advocate extensive surgery, or suggest the adjuvant use of chemo-
therapy. Tumor lysis syndrome (TLS), which results from the rapid malignant cell 
lysis, is a well recognized complication during treatment of rapidly growing tumors. 
Consequences of rapid cellular destruction include hyperuricemia, hyperkalemia, and 
hypocalcemia. These abnormalities may lead to acute renal failure. In this case, we 
describe a rare case of TLS in a man with primary retroperitoneal soft tissue sarcoma 
after chemotherapy by ex vivo ATP-based tumor chemosensitivity assay (ATP-TCA). 
ATP-TCA is an effective and easy-to-use methodology to selectively fresh isolated 
tumor cells. A major advantage over previous approaches is that the ATP-TCA respects 
the interaction sarcomas and the surrounding stromal cells. Using this test system, 
we were able to show that retroperitoneal soft tissue sarcomas display remarkable 
chemosensitivity to different anticancer agents.
Case report
A 44-year-old man had one-month history of progressively worsening abdominal 
distention and pain, pantothenic acid, nausea, 5 kg weight loss. On physical examina-
tion, the patient had abdominal eminence and a ﬁ  rm, border-less mass was palpable 
in central abdominal. Abdominal magnetic resonance imaging (MRI) revealed an 
occupancy mass of 21 × 18 cm in left posterolateral peritoneum, the left kidney International Journal of General Medicine 2009:2 2
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and lumbar muscle invasion, obstruction of left ureter, and 
hydronephrosis (Figure 1A). The left renal artery and 
renal veins were all compressed and the inferior vena cave 
showed thrombosis (Figure 1C). Laboratory testing revealed 
that the patient had serum lactate dehydrogenase (LDH) 
of 1365.4 U/L (normal range: 50–240 U/L), serum urea 
nitrogen of 2.8 mmol/L (normal range: 1.7 to 8.2 mmol/
L), serum creatinine of 74.3 μmol/L (normal range: 
0–124.0 μmol/L), serum uric acid of 331.0 μmol/L (normal 
range: 0–419.0 μmol/L), serum calcium of 2.35 mmol/L 
(normal range: 2.0–2.6 mmol/L), serum phosphate of 
1.1 mmol/L (normal range: 0.8–1.5 mmol/L), serum alpha-
fetoprotein (AFP) of 6756 μg/L (normal range: 0–7 μg/L), 
serum neuron-speciﬁ  c enolase (NSE) of 40.37 μg/L (normal 
range: 0–15.2 μg/L). Abdominal tumor biopsy samples were 
obtained using real-time B ultrasound-guided ﬁ  ne needle 
(16G). The biopsy specimens confirmed a histological 
diagnosis of primary retroperitoneal soft tissue sarcoma 
with hematoxylin and eosin staining (Figures 2A, 2B). 
Immunohistochemistry demonstrated a positive staining for 
vimentin (VIM) (Figure 2C), epithelial membrane antigen 
(EMA) (Figure 2D) and platelet endothelial cell adhesion 
molecule-1 (PECAM-1). The tumor sections had negative 
stainings for cytokeratin 7, synaptophysin, chromogranin A, 
CD57 and cytokeratin 20 (data not shown). The ex vivo biopsy 
specimens were detected by ATP-TCA testing (ATP-TCA, 
DCS Innovative Diagnostic Systems®, Hamburg, Germany).1 
It revealed the strong sensitivity of cisplatin (DDP), 
adriamycin (ADM) and dacarbazine (DTIC), the resistances 
of paclitaxe, vindesine, bleomycin, ifosfamide, and actino-
mycin D. The patient was given a combined chemotherapy 
regimen with DDP (30 mg/m2 intravenously on days 1 
through 4), ADM (30 mg/m2 intravenously on days 1, 3), 
and DTIC (400 mg/m2 intravenously on days 1 through 3) 
on the basis of the ATP-TCA in a three-week cycle. Three 
days after initiating chemotherapy, the patient felt weary 
seriously but drowsiness with normal urinary production. 
Four days after initiating chemotherapy, the patient 
A
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Figure 1 Magnetic resonance imaging (MRI) shows a bulky abdominal neoplasm at the left posterolateral position of abdomen with compression of kidney, renal artery and 
renal veins on the left side (A). MRI after 3 cycles of chemotherapy reveals complete remission of the tumor with cystic degeneration and necrosis of the tumor mass (B).International Journal of General Medicine 2009:2 3
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felt chest tightness, palpitations, dyspnea, and oliguria. 
Laboratory testing revealed evidence of acute renal failure as 
indicated by serum LDH level of 1565.4 U/L (normal range: 
50–240 U/L), serum urea nitrogen of 7.2 mmol/L (normal 
range: 1.7–8.2 mmol/L), serum creatinine of 143.0 μmol/L 
(normal range: 0–124.0 μmol/L), serum uric acid of 
584.0 μmol/L (normal range: 0–419.0 μmol/L), serum calcium 
of 1.7 mmol/L (normal range: 2.0–2.6 mmol/L), and serum 
phosphate of 2.3 mmol/L (normal range: 0.8–1.5 mmol/L). 
An ultrasonographic examination showed no evidence of 
extrarenal obstruction or renal vein thrombosis. A chemo-
therapy-induced tumor lysis syndrome (TLS) generated and 
DDP was immediately discontinued. Metabolic abnormalities 
were treated successfully using a combination of sodium 
bicarbonate, furosemide, and allopurinol. The serum levels 
of urea nitrogen, creatinine, uric acid, calcium, and phos-
phate were normalized. The blood LDH level decreased to 
365.4 U/L on day 12 after the treatment. The second and 
the third chemotherapy cycles were continued until three 
weeks after initiation of chemotherapy, accompanying with 
allopurinol, diuretic, alkaline urine. The therapeutic effects 
of the patient were evaluated at the 30th day following the 
third chemotherapy cycle. The patient’s abdominal distention 
and pain were relieved. The abdominal mass was impalpable 
on physical examination. The abdominal MRI revealed 
the tumor was partial remission with cystic degeneration 
and the mass was necrosis (Figure 1B). Laboratory testing 
revealed a serum LDH level of 143.0 U/L, serum AFP of 
510.0 μg/L and NSE of 14.7 μg/L.
Discussion
TLS is observed most frequently in patients with hematologic 
malignancies such as acute lymphoblastic leukemia (ALL) 
and Burkitt’s lymphoma after the initiation of chemotherapy, 
although it may also occur in other malignancies, both hema-
tologic and solid tumors. For the past few years, a variety 
of solid tumors have been reported to be associated with 
this syndrome,2 including tumors in the brain, lung, ovary, 
stomach, and skin.3–5 Our work presented a case of TLS in 
a patient with primary retroperitoneal soft tissue sarcoma 
that occurred after four days’ chemotherapy with DDP, 
ADM, and DTIC. DDP can lead to clinical and laboratory 
evidence of acute renal failure, but mainly damaged renal 
epithelial, not typical of the TLS metabolic disorder and 
slow restoration. This is a typical case of metabolic disorders 
initiating chemotherapy and no similar syndrome in further 
chemotherapy. We speculate DDP lead to acute renal failure 
can be ruled out.
Certain intrinsic tumor-related factors have been associ-
ated with an increased risk for the development of TLS, 
including high tumor cell proliferation rate, large tumor 
burden, tumor chemosensitivity, and increased LDH levels. 
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Figure 2 Histological analysis of the biopsy tumor specimen by .hematoxylin and eosin staining of the tumor (A, X100; B, X400) indicates diagnosis of primary retroperitoneal 
soft tissue sarcoma. The tumor samples were positive in immunohistochemical analysis for vimentin (C) and epithelial membrane antigen (D).International Journal of General Medicine 2009:2 4
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In our patient, several risk factors might predispose TLS. 
The first risk factor was chemosensitivity for primary 
retroperitoneal soft tissue sarcoma. Soft tissue sarcomas 
comprise less than 1% of all solid malignancies. The role of 
chemotherapy is not clearly deﬁ  ned and is largely restricted 
to clinical trials. Only a limited number of agents have 
proved to be effective in soft tissue sarcomas. Lehnhardt 
and colleagues also reported sensitivity testing in soft tissue 
sarcomas.6 It is expected that the pre-therapeutic sensitivity 
testing of cytotoxicity with ATP-TCA would provide the 
opportunity of improving the success rate of conventional 
chemotherapy in soft tissue sarcomas, as observed in this 
study. However, individualized chemotherapy protocol eval-
uated by ATP-TCA testing should be combined with clinical 
data in practice. The combination of chemotherapy used in 
the patient with primary retroperitoneal soft tissue sarcoma 
was chosen by an ATP-TCA testing system to determine 
the sensitivity of cultured tumor cells to various anti-tumor 
drugs. The biopsy specimens were difﬁ  cult to achieve for 
inoperableness patient. In this case, abdominal tumor biopsy 
can be done by cutting a small piece of the tissue specimens 
on real-time B ultrasound-guided ﬁ  ne needle. The strong 
sensitivity of DDP, ADM and DTIC by ex vivo ATP-TCA in 
the patient was conﬁ  rmed with TLS. The initiating chemo-
therapy and the abdominal MRI revealed partial remission 
of the tumor with cystic degeneration and necrosis of the 
tumor mass. The next risk factor was large tumor burden 
in the patient. Abdominal MRI revealed a giant occupancy 
mass of 21 × 18 cm in left posterolateral peritoneum, the left 
kidney, and lumbar muscle invasion. The third risk factor was 
increased LDH levels. The serum LDH level was markedly 
increased in the patient, accompanied with a slight increase 
of serum uric acid level before the initiating chemotherapy.
The fourth risk factors was urethral obstruction and kidney 
blood ﬂ  ow reduction in the patient. Abdominal MRI revealed 
obstruction of left ureter, hydronephrosis, the left renal artery 
and renal veins were all compressed, and inferior vena cave 
was thrombosis. The cellular components from malignant 
cells rapid lysis with chemotherapy into the blood following 
signiﬁ  cantly reduced, induced, or exacerbated TLS.
In our view, precautions should be taken to avoid this 
potentially fatal complication when treating solid tumors, 
especially in drug-sensitive tumors with bulky size and 
rapid progression. Several pre-existing risk factors such as 
azotemia, elevated LDH, and hyperuricemia should also be 
considered for the potential development of TLS. In sum-
mary, identifying patients at risk, implementing preventive 
measures and initiating prompt therapies to treat TLS at early 
recognition are all essential for avoiding serious complica-
tions associated with TLS.
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